Daily Endocrinology Research Analysis
Three studies reshape endocrine-metabolic practice: a phase III RCT shows the pan-PPAR agonist chiglitazar significantly improves glycemic and lipid profiles when added to metformin; a large German cohort links SGLT2 inhibitors to a lower 5-year incidence of iron deficiency anemia versus DPP-4 inhibitors; and a nationally representative Indian survey reveals an exceptionally high prevalence of metabolically unhealthy phenotypes among non-obese individuals, urging a shift from BMI-centric care to
Summary
Three studies reshape endocrine-metabolic practice: a phase III RCT shows the pan-PPAR agonist chiglitazar significantly improves glycemic and lipid profiles when added to metformin; a large German cohort links SGLT2 inhibitors to a lower 5-year incidence of iron deficiency anemia versus DPP-4 inhibitors; and a nationally representative Indian survey reveals an exceptionally high prevalence of metabolically unhealthy phenotypes among non-obese individuals, urging a shift from BMI-centric care to metabolic risk targeting.
Research Themes
- Pan-PPAR therapeutics for type 2 diabetes
- SGLT2 inhibitors and hematologic outcomes
- Redefining obesity by metabolic risk in population health
Selected Articles
1. Efficacy and safety of chiglitazar add-on to metformin in type 2 diabetes mellitus (RECAM study).
In a 24-week, randomized, double-blind phase III trial of 533 Chinese adults with T2D on metformin, chiglitazar lowered HbA1c by −0.91% (32 mg) and −1.14% (48 mg) versus −0.49% with placebo, and improved triglycerides, free fatty acids, and HDL-C. Adverse events were comparable, with slight increases in weight and mild edema in chiglitazar groups.
Impact: This high-quality RCT introduces a pan-PPAR agent with dual glycemic and lipid benefits, addressing residual cardiometabolic risk beyond glucose lowering. It supports a mechanistically distinct option for patients inadequately controlled on metformin.
Clinical Implications: Chiglitazar may be considered as an add-on to metformin for patients needing both HbA1c reduction and atherogenic lipid improvement, with counseling about modest weight gain and edema and ongoing monitoring for long-term cardiovascular outcomes.
Key Findings
- At 24 weeks, HbA1c reduction was −0.91% (32 mg) and −1.14% (48 mg) versus −0.49% with placebo (both p < 0.001).
- Improvements included lower fasting and 2-hour postprandial glucose, reduced triglycerides and free fatty acids, and increased HDL-C.
- Adverse events were similar across groups; slight increases in weight and mild edema occurred with chiglitazar.
Methodological Strengths
- Randomized, double-blind, placebo-controlled phase III design with prespecified primary endpoint.
- Clinically meaningful metabolic endpoints (HbA1c, fasting/postprandial glucose, triglycerides, HDL-C) with clear between-group differences.
Limitations
- 24-week duration limits assessment of long-term efficacy and cardiovascular outcomes.
- Study population limited to Chinese adults; generalizability to other ethnicities and comorbidity profiles is uncertain.
Future Directions: Conduct longer-term outcome trials assessing cardiovascular and renal endpoints, and comparative effectiveness studies versus GLP-1RA/SGLT2i in diverse populations.
AIMS: Chiglitazar is a novel peroxisome proliferator-activated receptor pan-agonist regulating glucose and lipid metabolism. The RECAM study aimed to evaluate the efficacy and safety of chiglitazar add-on therapy to metformin in patients with type 2 diabetes mellitus (T2DM). MATERIALS AND METHODS: In this randomised, double-blind, phase III trial (NCT04807348), 533 patients with T2DM inadequately controlled by metformin were randomly assigned in a 1:1:1 ratio to receive chiglitazar 32 mg (n = 178), chiglitazar 48 mg (n = 177), or placebo (n = 178) for 24 weeks, in addition to metformin. The primary endpoint was the change in glycosylated haemoglobin (HbA1c) from baseline to week 24. RESULTS: At week 24, the least squares mean changes in HbA1c were -0.91% (95% CI: -1.03% to -0.79%) in the chiglitazar 32 mg group, -1.14% (95% CI: -1.26% to -1.02%) in the chiglitazar 48 mg group, and -0.49% (95% CI: -0.62% to -0.36%) in the placebo group. Both chiglitazar 32 mg and 48 mg significantly reduced HbA1c compared to placebo (both p < 0.001), with the reduction being greater in the 48 mg group than in the 32 mg group (p = 0.008). Chiglitazar significantly improved fasting plasma glucose and 2-h postprandial glucose while reducing triglyceride and free fatty acid levels and increasing high-density lipoprotein cholesterol levels. The incidence of adverse events was comparable across groups, with a slight increase in weight gain and mild oedema observed in the chiglitazar groups. CONCLUSIONS: Chiglitazar combined with metformin significantly improves glycaemic control and lipid metabolism in Chinese patients with T2DM who are inadequately managed with metformin and have a favourable safety profile. TRIAL REGISTRATION: ClinicalTrials.gov (NCT04807348).
2. High prevalence of metabolic obesity in India: The ICMR-INDIAB national study (ICMR-INDIAB-23).
In a nationally representative sample of 113,043 Indian adults, metabolically obese non-obese (MONO) individuals comprised 43.3% and metabolically obese obese (MOO) 28.3%, whereas metabolically healthy obese were rare (1.8%). MOO had the highest T2D and CAD risk, while MONO had the highest CKD risk—especially in women—highlighting the need for metabolic risk–based screening beyond BMI.
Impact: This large, contemporary, population-based study quantifies metabolically unhealthy phenotypes across BMI categories, directly informing national screening and prevention strategies.
Clinical Implications: Clinicians should screen for metabolic risk (waist, BP, glucose, triglycerides, HDL-C) regardless of BMI, particularly in women and rural populations, and tailor CKD, T2D, and CAD prevention accordingly.
Key Findings
- Prevalence: MONO 43.3% (95% CI 42.6–44.0), MOO 28.3% (27.7–28.9), MHNO 26.6% (26.0–27.2), MHO 1.8% (1.6–2.0).
- MONO prevalence was higher in rural than urban areas: 46.0% vs 39.6% (P < 0.001).
- MOO carried the highest risk of T2D and CAD, whereas MONO carried the highest risk of CKD, especially among females.
Methodological Strengths
- Nationally representative, very large sample across 31 states/territories with standardized definitions.
- Biochemical measurements in a substantial subsample (n=19,370) enhancing phenotype classification.
Limitations
- Cross-sectional design precludes causal inference for disease risk.
- Potential measurement and classification biases across diverse field settings; limited granularity on treatment status.
Future Directions: Prospective follow-up to quantify incident T2D/CAD/CKD by phenotype, and interventional studies targeting MONO to test whether early metabolic risk modification reduces CKD risk.
Background & objectives While obesity usually produces cardio-metabolic dysfunction, some obese individuals are metabolically healthy, and conversely, some nonobese individuals have significant metabolic dysfunction. This study aims to assess the national prevalence of various obesity subtypes and their association with type 2 diabetes (T2D), coronary artery disease (CAD), and chronic kidney disease (CKD) in the Indian Council of Medical Research-India Diabetes (ICMR-INDIAB) study. Methods The ICMR-INDIAB study is a nationally representative cross-sectional survey of 1,13,043 individuals aged ≥20 yr from urban and rural areas across 31 Indian States and Union Territories. In every fifth individual (n=19,370), venous blood glucose and lipids were measured. A body mass index (BMI) ≥25 kg/m2 was defined as being obese, and metabolic obesity was diagnosed if two risk factors, out of the following: high waist circumference, high blood pressure, elevated blood glucose, raised serum triglycerides, or low HDL cholesterol, were present. Four subgroups were identified: Metabolically Healthy Non-Obese (MHNO), Metabolically Healthy Obese (MHO), Metabolically Obese Non-Obese (MONO), and Metabolically Obese Obese (MOO). Results The prevalence of various obesity subtypes was as follows: MONO: 43.3 per cent [95% confidence interval (CI): 42.6-44%], MOO: 28.3 per cent (27.7-28.9%), MHNO: 26.6 per cent (26-27.2%), and MHO: 1.8 per cent (1.6-2%). MONO was more prevalent in rural areas [Rural vs. Urban: MONO: 46 per cent (45-46.9%) vs. 39.6 per cent (37.8-41.3%), P<0.001]. MOO showed the highest risk for T2D and CAD, while MONO showed the highest risk of CKD, especially among females. Interpretation & conclusions Individuals with MONO have a distinct phenotype with adverse metabolic consequences, highlighting the need to shift from body weight-focused approaches to broader strategies to identify and tackle non-communicable diseases (NCDs) in India.
3. SGLT2 inhibitor therapy and lower incidence of iron deficiency anaemia in patients with type 2 diabetes: A retrospective cohort study from Germany.
Among 56,882 propensity-matched German adults with T2D initiating add-on therapy to metformin, SGLT2 inhibitors were associated with a lower 5-year incidence of iron deficiency anemia than DPP-4 inhibitors (6.9% vs 11.3%; HR 0.67). Benefits were consistent in men and those >60 years, with attenuation after prolonged metformin use.
Impact: The study reveals a potentially important hematologic advantage of SGLT2 inhibitors, expanding their benefit profile beyond cardiorenal outcomes and informing drug selection in T2D with anemia risk.
Clinical Implications: For T2D patients at risk for iron deficiency anemia, SGLT2 inhibitors may be preferred over DPP-4 inhibitors when clinically appropriate, with continued monitoring of hematologic parameters.
Key Findings
- Cumulative 5-year IDA incidence: 6.9% (SGLT2i) vs 11.3% (DPP-4i), p < 0.001.
- Hazard ratio for IDA with SGLT2i vs DPP-4i: 0.67 (95% CI 0.58–0.78).
- Protective association consistent in males and >60 years; attenuated with metformin use ≥3 years.
Methodological Strengths
- Large real-world dataset with rigorous 1:1 propensity score matching and 5-year follow-up.
- Consistent results across key subgroups and time-to-event analyses (KM, Cox).
Limitations
- Observational design susceptible to residual confounding and outcome misclassification.
- Lack of direct iron indices and mechanisms; restricted to German office-based practices.
Future Directions: Prospective randomized trials to test SGLT2i effects on anemia incidence and iron metabolism, with mechanistic biomarkers (EPO, ferritin, hepcidin) and diverse populations.
AIMS: Iron deficiency anaemia (IDA) is a common comorbidity in patients with type 2 diabetes mellitus (T2DM). Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been shown to modulate erythropoiesis and iron metabolism, but their association remains unclear. This cohort study investigated whether SGLT2i use, compared to dipeptidyl peptidase-4 inhibitors (DPP-4i), is associated with a lower incidence of IDA in T2DM. MATERIALS AND METHODS: We analysed data from the IQVIA™ Disease Analyzer, a German electronic medical records database (ICD-10) from office-based practices. Patients with T2DM (≥18 years) who initiated SGLT2i or DPP-4i therapy alongside metformin between 2012 and 2022 were included. Those with prior anaemia diagnoses were excluded. Propensity score matching (1:1) was performed based on age, sex, baseline HbA1c, duration of metformin use, and anaemia-related comorbidities. Kaplan-Meier analyses and Cox proportional hazards regression models were used to compare IDA incidence between cohorts over a 5-year follow-up. RESULTS: In total 28 441 propensity score matched patients per cohort were analysed. The cumulative 5-year incidence of IDA was significantly lower in the SGLT2i (6.9%) versus DPP-4i cohort (11.3%) (p < 0.001). SGLT2i use was associated with a decreased risk of IDA (HR: 0.67; 95% CI: 0.58-0.78). Subgroup analyses confirmed this association in males and elder patients (>60 years), while the protective effect was limited to metformin use under 3 years. CONCLUSION: SGLT2i therapy was associated with a lower incidence of IDA in T2DM patients compared to DPP-4i therapy. These findings suggest a potential hematologic benefit of SGLT2 inhibitors, warranting further investigation in randomised controlled trials.